It is applied once a week for three weeks, with the fourth week being hormone-free to allow for a period
Potential treatment of cardiac hypertrophy and heart failure by inhibiting the sarcolemmal binding of phospholipase C1b
It has a broader evidence base, lower per-dose cost, and versatile administration routes
It is not surprising that hepatic T3 signaling has a metabolic effect similar to those observed after nutrition ingestion on incretin GLP-1 through the regulation of CYP8B1 and non-12-OH FXR-antagonistic BAs
doi:10.1038/s41398-019-0515-5 Paddon-Jones D, Westman E, Mattes RD, Wolfe RR, Astrup A, Westerterp-Plantenga M
Retatrutide handles the heavy lifting on appetite and metabolism, while AOD-9604 fills a gap that no incretin-based peptide can address: direct, receptor-level stimulation of fat breakdown